Your browser doesn't support javascript.
loading
Risk of Cognitive Impairment in Patients With Parkinson's Disease With Visual Hallucinations and Subjective Cognitive Complaints.
Santos-García, Diego; de Deus Fonticoba, Teresa; Cores Bartolomé, Carlos; Feal Painceiras, Maria J; Paz González, Jose M; Martínez Miró, Cristina; Jesús, Silvia; Aguilar, Miquel; Pastor, Pau; Planellas, Lluís; Cosgaya, Marina; García Caldentey, Juan; Caballol, Nuria; Legarda, Ines; Hernández Vara, Jorge; Cabo, Iria; López Manzanares, Lydia; González Aramburu, Isabel; Ávila Rivera, Maria A; Gómez Mayordomo, Víctor; Nogueira, Víctor; Puente, Víctor; Dotor García-Soto, Julio; Borrué, Carmen; Solano Vila, Berta; Álvarez Sauco, María; Vela, Lydia; Escalante, Sonia; Cubo, Esther; Carrillo Padilla, Francisco; Martínez Castrillo, Juan C; Sánchez Alonso, Pilar; Alonso Losada, Maria G; López Ariztegui, Nuria; Gastón, Itziar; Kulisevsky, Jaime; Blázquez Estrada, Marta; Seijo, Manuel; Rúiz Martínez, Javier; Valero, Caridad; Kurtis, Mónica; de Fábregues, Oriol; González Ardura, Jessica; Alonso Redondo, Ruben; Ordás, Carlos; López Díaz L, Luis M; McAfee, Darrian; Martinez-Martin, Pablo; Mir, Pablo.
Afiliação
  • Santos-García D; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. diegosangar@yahoo.es.
  • de Deus Fonticoba T; CHUF, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain.
  • Cores Bartolomé C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Feal Painceiras MJ; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Paz González JM; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Martínez Miró C; CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.
  • Jesús S; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
  • Aguilar M; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Pastor P; Hospital Universitari Mutua de Terrassa, Terrassa, Spain.
  • Planellas L; Hospital Universitari Mutua de Terrassa, Terrassa, Spain.
  • Cosgaya M; Clínica del Pilar, Barcelona, Spain.
  • García Caldentey J; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Caballol N; Centro Neurológico Oms 42, Palma de Mallorca, Spain.
  • Legarda I; Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Spain.
  • Hernández Vara J; Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Cabo I; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • López Manzanares L; Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • González Aramburu I; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • Ávila Rivera MA; Hospital Universitario La Princesa, Madrid, Spain.
  • Gómez Mayordomo V; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Nogueira V; Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Puente V; Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Dotor García-Soto J; Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Borrué C; Hospital Da Costa, Burela, Lugo, Spain.
  • Solano Vila B; Hospital del Mar, Barcelona, Spain.
  • Álvarez Sauco M; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Vela L; Hospital Infanta Sofía, Madrid, Spain.
  • Escalante S; Institut d'Assistència Sanitària (IAS)-Institut Català de la Salut, Girona, Spain.
  • Cubo E; Hospital General Universitario de Elche, Elche, Spain.
  • Carrillo Padilla F; Fundación Hospital de Alcorcón, Madrid, Spain.
  • Martínez Castrillo JC; Hospital de Tortosa Verge de la Cinta (HTVC), Tortosa, Spain.
  • Sánchez Alonso P; Complejo Asistencial Universitario de Burgos, Burgos, Spain.
  • Alonso Losada MG; Hospital Universitario de Canarias, San Cristóbal de la Laguna, Spain.
  • López Ariztegui N; Hospital Universitario Ramón y Cajal, RYCIS, Madrid, Spain.
  • Gastón I; Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Kulisevsky J; Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain.
  • Blázquez Estrada M; Complejo Hospitalario de Toledo, Toledo, Spain.
  • Seijo M; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Rúiz Martínez J; CIBERNED (Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas), Madrid, Spain.
  • Valero C; Hospital de Sant Pau, Barcelona, Spain.
  • Kurtis M; Hospital Universitario Central de Asturias, Oviedo, Spain.
  • de Fábregues O; Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain.
  • González Ardura J; Hospital Universitario Donostia, San Sebastián, Spain.
  • Alonso Redondo R; Hospital Arnau de Vilanova, Valencia, Spain.
  • Ordás C; Hospital Ruber Internacional, Madrid, Spain.
  • López Díaz L LM; Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • McAfee D; Hospital de Cabueñes, Gijón, Spain.
  • Martinez-Martin P; Universitario Lucus Augusti (HULA), Lugo, Spain.
  • Mir P; Hospital Rey Juan Carlos, Madrid, Spain.
J Clin Neurol ; 19(4): 344-357, 2023 Jul.
Article em En | MEDLINE | ID: mdl-36647231
ABSTRACT
BACKGROUND AND

PURPOSE:

Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson's disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson's disease and normal cognition (PD-NC).

METHODS:

Patients with PD-NC (total score of >80 on the Parkinson's Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of ≥1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as "with SCC" and "with VH," respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81.

RESULTS:

At V0 (n=376, 58.2% males, age 61.14±8.73 years [mean±SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05-6.83, p=0.0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36-10.17, p=0.011).

CONCLUSIONS:

VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Clin Neurol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Clin Neurol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha